期刊文献+

长效胰岛素联合口服降糖药治疗2型糖尿病的临床观察 被引量:13

Clinical Observation of Long-acting Insulin and Oral Hypoglycemic Agents in the Treatment of Type 2 Diabetes
下载PDF
导出
摘要 目的观察长效胰岛素联合口服降糖药治疗2型糖尿病的临床疗效。方法收集2型糖尿病患者104例,随机分为观察组(长效胰岛素+口服降糖药)与对照组(单用长效胰岛素)。结果治疗前,两组FBG、2 h PBG及Hb Alc对比,无差异(P>0.05);治疗后,观察组FBG、2 h PBG及Hb Alc均优于对照组,差异具有统计学意义(P<0.05);两组低血糖发生率比较,差异具有统计学意义(P<0.05),结论长效胰岛素+口服降糖药治疗2型糖尿病疗效显著。 Objective To observe the clinical efficacy of long-acting insulin in type 2 diabetes combined with oral hypoglycemic agents. Methods 104 cases of type 2 diabetes were randomly divided into two groups(long-acting insulin and oral hypoglycemic agents)and control group(single long-acting insulin). Results Before treatment,the two groups FBG,2 h PBG and Hb Alc contrast,no significant difference(P〈0.05),after treatment,the observation group FBG,2 h PBG and Hb Alc were better than the control group,the difference was significant(P〈0.05). View groups the incidence of hypoglycemia,the difference was significant(P〈0.05). Conclusion The long-acting insulin and oral hypoglycemic agents to treat type 2 diabetes a significant effect.
作者 冯克棘
出处 《中国卫生标准管理》 2016年第1期100-101,共2页 China Health Standard Management
关键词 长效胰岛素 降糖药 2型糖尿病 Long-acting insulin Hypoglycemic agents Type 2 diabetes
  • 相关文献

参考文献8

二级参考文献94

  • 1Claudia Filozof,Sherwyn Schwartz,James E Foley.Effect of vildagliptin as add-on therapy to a low-dose metformin[J].World Journal of Diabetes,2010,1(1):19-26. 被引量:8
  • 2金文波,黄文平,徐娜,金毅,陈丽君.强化治疗对初诊2型糖尿病β细胞功能影响的研究[J].实用诊断与治疗杂志,2005,19(1):14-15. 被引量:4
  • 3何志高,丁奇峰,金丽.二甲双胍与阿卡波糖分别联合胰岛素治疗2型糖尿病的最小成本分析[J].中国药房,2005,16(10):750-751. 被引量:11
  • 4毕艳,孙卫平,翁建平.初发2型糖尿病病人短期强化胰岛素治疗胰岛素抵抗改善的可能机制[J].中华医学杂志,2007,87(18):1284-1286. 被引量:38
  • 5陈燕铭.糖尿病的最新诊断标准.国际医药卫生导报,1999,5(5):35-35.
  • 6Danaei G, Finucane M M, Lu Yuan, et al. National, region- al, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examina- tion surveys and epidemiological studies with 370 country-years and 2 7 million participants[J]. The Lancet, 2011, 378 (9785) : 31-40.
  • 7Consultation W H O. Definition, diagnosis and classification of diabetes mellitus and its complications[M]. Geneva, 1999.
  • 8Mathers C D, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030[J]. PLoS Medicine, 2006, 3(11): e442.
  • 9DeFronzo R A, Fleck P. R, Wilson C A, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in pa- tients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study[J]. Dia- betes Care, 2008, 3l(12) :2315-2317.
  • 10Nauck M A, Ellis G C, Fleck P R, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to met- formin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, ran- domised, double-blind, placebo-controlled study[J]. Int J Clin Pract, 2009, 63(1): 46-55.

共引文献77

同被引文献45

引证文献13

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部